Literature DB >> 17406149

Thromboendarterectomy as treatment in the antiphospholipid syndrome.

Suzette W Peng1, Jeanne P Mitchell.   

Abstract

Antiphospholipid antibody syndrome (APS) may lead to pulmonary hypertension, a lethal complication of chronic pulmonary thromboembolism. There are few viable treatment options for pulmonary hypertension, but pulmonary thromboendarterectomy (PTE) has been used to successfully treat this condition in many patient populations. Following is a description of a patient with APS and systemic lupus erythematosus (SLE) who presented with severe pulmonary hypertension and underwent lifesaving surgery with pulmonary thromboendarterectomy. Successful intervention with thromboendarterectomy for the treatment of severe pulmonary hypertension is possible in patients with the antiphospholipid antibody syndrome, and surgical referral of these patients is warranted.

Entities:  

Mesh:

Year:  2006        PMID: 17406149      PMCID: PMC1781316     

Source DB:  PubMed          Journal:  MedGenMed        ISSN: 1531-0132


  15 in total

1.  Long-term outcome after pulmonary thromboendarterectomy.

Authors:  C J Archibald; W R Auger; P F Fedullo; R N Channick; K M Kerr; S W Jamieson; D P Kapelanski; C N Watt; K M Moser
Journal:  Am J Respir Crit Care Med       Date:  1999-08       Impact factor: 21.405

2.  Operation for chronic pulmonary thromboembolism accompanied by thrombophilia in 8 patients.

Authors:  M Ando; S Takamoto; Y Okita; R Matsukawa; N Nakanishi; S Kyotani; T Satoh
Journal:  Ann Thorac Surg       Date:  1998-12       Impact factor: 4.330

Review 3.  Our experience of surgical treatment for chronic pulmonary thromboembolism.

Authors:  M Masuda; N Nakajima
Journal:  Ann Thorac Cardiovasc Surg       Date:  2001-10       Impact factor: 1.520

Review 4.  Management of antiphospholipid antibody syndrome: a systematic review.

Authors:  Wendy Lim; Mark A Crowther; John W Eikelboom
Journal:  JAMA       Date:  2006-03-01       Impact factor: 56.272

Review 5.  Chronic thromboembolic pulmonary hypertension.

Authors:  P F Fedullo; W R Auger; R N Channick; K M Kerr; L J Rubin
Journal:  Clin Chest Med       Date:  2001-09       Impact factor: 2.878

6.  Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data.

Authors:  M Riedel; V Stanek; J Widimsky; I Prerovsky
Journal:  Chest       Date:  1982-02       Impact factor: 9.410

7.  Comparative outcome of heart-lung and lung transplantation for pulmonary hypertension.

Authors:  A Chapelier; P Vouhé; P Macchiarini; B Lenot; J Cerrina; F Le Roy Ladurie; F Parquin; P Hervé; F Brenot; D Lafont
Journal:  J Thorac Cardiovasc Surg       Date:  1993-08       Impact factor: 5.209

8.  Pulmonary endarterectomy: experience and lessons learned in 1,500 cases.

Authors:  Stuart W Jamieson; David P Kapelanski; Naohide Sakakibara; Gerard R Manecke; Patricia A Thistlethwaite; Kim M Kerr; Richard N Channick; Peter F Fedullo; William R Auger
Journal:  Ann Thorac Surg       Date:  2003-11       Impact factor: 4.330

9.  The management of thrombosis in the antiphospholipid-antibody syndrome.

Authors:  M A Khamashta; M J Cuadrado; F Mujic; N A Taub; B J Hunt; G R Hughes
Journal:  N Engl J Med       Date:  1995-04-13       Impact factor: 91.245

10.  Primary antiphospholipid syndrome presenting as chronic thromboembolic pulmonary hypertension. Treatment with thromboendarterectomy.

Authors:  J Sandoval; M C Amigo; R Barragan; R Izaguirre; P A Reyes; M L Martinez-Guerra; A Palomar; A Gomez; R Garcia-Torres
Journal:  J Rheumatol       Date:  1996-04       Impact factor: 4.666

View more
  1 in total

1.  Pulmonary Endarterectomy in Patients with Antiphospholipid Syndrome-Associated Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Serpil Taş; Arzu Antal; Ali Fuad Durusoy; Mehmed Yanartaş; Kübra Yıldız; Şehnaz Olgun Yıldızeli; Derya Kocakaya; Bülent Mutlu; Fatma Alibaz-Öner; Haner Direskeneli; Nevsun İnanç; Atakan Erkılınç; Bedrettin Yıldızeli
Journal:  Anatol J Cardiol       Date:  2022-05       Impact factor: 1.475

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.